Summary & Overview
HCPCS Level II Q0222: Injection, bebtelovimab, 175 mg
HCPCS Level II code Q0222 denotes the administration of bebtelovimab, 175 mg, a monoclonal antibody injection used as a therapeutic agent. Nationally, this HCPCS Level II code matters because it identifies a specific biologic treatment given in outpatient settings and informs coverage, billing, and utilization tracking for novel antibody therapies. Its use affects reimbursement flows, provider billing practices, and claims adjudication for outpatient infusion services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for bebtelovimab injections, typical sites of service, and the role of Q0222 in claims processing. The publication summarizes common payer coverage patterns, relevant benchmarks for service lines, and recent policy developments impacting billing and reimbursement for monoclonal antibody injections.
The content outlines what providers and billing teams need to identify on claims (service descriptor, site of service) and highlights where to look for payer-specific guidance. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code Q0222 describes the administration of injection, bebtelovimab, 175 mg. This code represents a single-dose injectable monoclonal antibody medication provided for clinical indications consistent with bebtelovimab therapy.
Service Type: Therapeutic monoclonal antibody injection
Typical Site of Service: Outpatient infusion center, clinic, or other outpatient administration settings
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 68-year-old ambulatory patient with multiple medical comorbidities presents to an outpatient infusion clinic within days of a confirmed mild-to-moderate SARS-CoV-2 infection. The patient is at high risk for progression to severe COVID-19 due to age and chronic conditions (for example, chronic obstructive pulmonary disease and congestive heart failure). The clinician documents current symptomatic COVID-19 infection and determines that monoclonal antibody therapy is appropriate. The ordered medication is Q0222 (injection, bebtelovimab, 175 mg).
The clinical workflow includes: triage and verification of positive SARS-CoV-2 test and symptoms, review of eligibility and contraindications, informed consent, preparation and administration of Q0222 via intravenous push or infusion per product labeling, monitoring for acute infusion-related reactions for at least 30 minutes post-administration, documentation of lot number and administration details in the medical record, and billing for the drug using Q0222 with any applicable CPT codes for infusion or observation services and appropriate modifiers as indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |